Phaseline

Companies › Laboratorios Sophia S.A de C.V.

Laboratorios Sophia S.A de C.V.: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Ophthalmology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Moxifloxacin (PRO-232)
Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor
GYRB, NR3C1Phase 3Cataract Extraction–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07305987Moxifloxacin (PRO-232)Phase 3Cataract ExtractionOphthalmologyJun 2026

Targets

GYRB (1) NR3C1 (1)

Companies with the same targets

Corcept Therapeutics Oticara Australia AstraZeneca Eupraxia Pharmaceuticals Alimera Sciences Optinose US Santhera Pharmaceuticals Pop Test Oncology Pacira Pharmaceuticals Tiohundra

Companies built like this

Alimera Sciences ReGenTree Ocus Innovation Ireland Ocumension Therapeutics (Suzhou) Alkeus Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.